Skip to main content
. 2016 Mar;13(1):87–100. doi: 10.28092/j.issn.2095-3941.2016.0010

Figure1.

Figure1

Key components of the PI3K pathway with possible therapeutic targets. Drugs targeting individual components are either in trials as noted, or were effective in vitro with cell lines containing PI3KCA mutations. The RAS/MEK/ERK pathway, which has been noted to play a role in resistance to PI3K-targeted therapies, is shown.